Press release
Minimal Residual Disease Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
Unlock key insights into the Minimal Residual Disease Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Minimal Residual Disease Market Size [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Minimal Residual Disease Market Report
* In April 2025, Janssen Research & Development LLC announced a study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
* In April 2025, Pfizer conducted a study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years.
* According to the statistics published by the American Cancer Society 2022, 34,470 new cases of multiple myeloma in the United States in 2022.
* About 6,660 new cases of acute lymphocytic leukemia (ALL) in 2022.
* As per the statistics published by the Leukemia and Lymphoma Society, in 2021, 90,390 new lymphoma cases were expected to be diagnosed in patients in the United States, of which 8,830 cases would be of Hodgkin lymphoma and 81,560 cases of non-Hodgkin lymphoma.
* The leading Minimal Residual Disease Companies such as Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology , and others
* Prominent Minimal Residual Disease Therapies such as ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR Registered PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis , and others.
Stay ahead in the competitive landscape of the Minimal Residual Disease Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Minimal Residual Disease Treatment Market Size [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Minimal Residual Disease Epidemiology Segmentation in the 7MM
* Total Minimal Residual Disease testing
* Total Minimal Residual Disease cases by cancer type
* Total Minimal Residual Disease testing from different blood cancers
* Total Minimal Residual Disease testing for HSCT-related transplant
* Total Minimal Residual Disease testing during new therapy and maintenance therapy
* Total number of Minimal Residual Disease Testing by age
Download the report to understand which factors are driving Minimal Residual Disease Epidemiology trends @ Minimal Residual Disease Prevalence [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Minimal Residual Disease Market Dynamics
The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.
Minimal Residual Disease Therapies and Companies
* ClonoSEQ: Adaptive Biotechnologies
* PhasED-Seq: Foresight Diagnostics
* Targeted Locus Amplification (TLA) technology: Cergentis B.V.
* MRDx BCR-ABL Test: ICON plc
* TRUPCR Registered PML-RARA: 3B BlacBio Biotech
* Signatera: Natera
* Leukemia Fusion Gene One-Step Detection Kits: EntroGen
* CBFB/MYH11 inv(16): Quest Diagnostics
* Seq-MRD: ImmuQuad
* PhasED-Seq: Foresight Diagnostics
* Targeted Locus Amplification (TLA) technology: Cergentis B.V.
* TRUPCR Registered PML-RARA: 3B BlacBio Biotech
* CBFB/MYH11 inv(16): Quest Diagnostics
* LymphoTrack: Invivoscribe Inc.
* Biocartis: Idylla Technology
Discover the future of Minimal Residual Disease Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Minimal Residual Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Minimal Residual Disease Market Report
* Coverage- 7MM
* Study Period- 2019-2032
* Minimal Residual Disease Companies- Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology , and others
* Minimal Residual Disease Therapies- ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR Registered PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis , and others.
* Minimal Residual Disease Market Dynamics: Minimal Residual Disease Market Drivers and Barriers
* Minimal Residual Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives
Explore the dynamics of the Minimal Residual Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Minimal Residual Disease Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/minimal-residual-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary of Minimal Residual Disease
3. Competitive Intelligence Analysis for Minimal Residual Disease
4. Minimal Residual Disease: Market Overview at a Glance
5. Minimal Residual Disease: Disease Background and Overview
6. Minimal Residual Disease Patient Journey
7. Minimal Residual Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Minimal Residual Disease Unmet Needs
10. Key Endpoints of Minimal Residual Disease Treatment
11. Minimal Residual Disease Marketed Products
12. Minimal Residual Disease Emerging Therapies
13. Minimal Residual Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Minimal Residual Disease Market Outlook
16. Access and Reimbursement Overview of Minimal Residual Disease
17. KOL Views
18. Minimal Residual Disease Market Drivers
19. Minimal Residual Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=minimal-residual-disease-treatment-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2032-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/minimal-residual-disease-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Minimal Residual Disease Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight here
News-ID: 3982288 • Views: …
More Releases from ABNewswire
Client Success Club Empowers Everyday People to Land High-Paying Remote Jobs as …
Client Success Club is transforming workforce access in the $3.2 billion online services industry.
Image: https://www.abnewswire.com/upload/2025/04/cd06dfefcaf387087c58c1f914271a38.jpg
As remote work continues to redefine professional landscapes, Client Success Club [https://clientsuccessclub.io/] is helping individuals from all backgrounds break into the booming online services industry by securing high-paying remote roles as Client Success Managers (CSMs). Combining expert-led training with direct placement services, Client Success Club is transforming lives by connecting aspiring professionals with growing online businesses…
Closana Launches a New Era of Capital Advisory: Raising Smarter, Faster, and Wit …
"Blitz Model" by Closana reshapes startup fundraising with execution-first strategies and real investor connections.
Image: https://www.abnewswire.com/upload/2025/04/e82e0f74d032313d51fb15f048368c1b.jpg
Closana [https://www.closana.ai/], a modern capital advisory platform, is setting a new standard for startup fundraising by offering execution-first support that delivers signed term sheets - not just advice. Designed for founders who prioritize results over rhetoric, Closana enables early-stage startups to raise $500K-$5M in capital with speed, precision, and real investor engagement.
With a focus on action…
Introducing "Underestimated" By David Kabithe, M.D., F.A.C.S.
Dr. David Kabithe, a dedicated surgeon and first-generation Kenyan/American, is proud to announce the release of his inspiring memoir, UNDERESTIMATED [https://www.amazon.com/Underestimated-Unlikely-Journey-Becoming-Surgeon-ebook/dp/B0DPD4392R]. This heartfelt book invites readers on a journey through his life, showcasing his struggles, triumphs, and steadfast determination to succeed despite the odds stacked against him.
UNDERESTIMATED [https://www.amazon.com/Underestimated-Unlikely-Journey-Becoming-Surgeon-ebook/dp/B0DPD4392R] is more than just a memoir; it is a powerful testament to resilience and growth. In this book, the author shares his…
Dr. Fatih Dagdelen Shares Safer Alternatives in Aesthetic Procedures, Highlighti …
Image: https://www.abnewswire.com/upload/2025/04/3a7d9663d4b4465578f4f72621239f53.jpg
With more than 32 years of experience, over 80,000 successful operations, and global recognition in the field of aesthetic surgery, Dr. Fatih Dagdelen is once again leading critical conversations about patient safety and natural results in cosmetic procedures. Speaking from his base in Istanbul at Dora Hospital, Dr. Dagdelen shared insights on the risks associated with high-volume filler and the growing preference for lip lift surgeries over traditional lip…
More Releases for Disease
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
